Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMISE immunosuppression trial for DMEK corneal transplantation
NL-OMON59633Phase 4Recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fluorometholone in corneal endothelial disease (CED), Keratoplasty, sponsored by Maastricht University Medical Center+. Started Jul 2024; status: recruiting.
02
Drugs
fluorometholone
03
Conditions
corneal endothelial disease (CED)Keratoplasty
Beyond the preview
Go deeper on NL-OMON59633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59633.